trending Market Intelligence /marketintelligence/en/news-insights/trending/tN42SsFNztMsQgEd3AiGZg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

European Commission extends market authorization of seizure drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


European Commission extends market authorization of seizure drug

The European Commission extended the marketed authorization of Zebinix to treat partial-onset seizures in children above the age of six.

The drug is already authorized for use in adults over the age of 18. It is marketed in Europe and Russia by Bial and by Bial's licensee, Eisai Europe Ltd.

Eisai Europe is an Eisai Co. Ltd. subsidiary.